Investment climate improves in US, says Burrill
This article was originally published in Clinica
At the same time Burrill & Co, a US merchant bank which invests solely in the life sciences sector, has noted a massive 63% increase in the volume of capital raised by the biotech industry in the second quarter. The industry's level of IPOs still remained below that of the same period last year, but venture capital and convertible debt brought into the industry totalled $1.4 billion.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.